CD20 and CD22 Therapies, Therapies Combination Therapies with a cell that expresses a Chimeric Antigen receptor (CAR) of CD19

摘要

The invention provides ingredients and methods for treating diseases related to CD19 expression, for example, managing a recombinant cell, including CD19 as described herein, plus one or more B-cell inhibitors, for example, one or more B-cell inhibitors. The invention of CD10, CD20, CD22, CD34, CD123, Flt-3, ror1, CD79b, cd179b or CD79a also provides new antigen binding domains and car molecules, which all point to CD20 and CD22 and their applications,For example, as a single therapy or combination therapy, the invention also provides the toolkit and components described in this document.